Comparative Pharmacology
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE versus SYMBICORT AEROSPHERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE versus SYMBICORT AEROSPHERE.
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE vs SYMBICORT AEROSPHERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelastine is a histamine H1-receptor antagonist that inhibits histamine release from mast cells; fluticasone propionate is a corticosteroid that suppresses inflammatory mediators including cytokines, prostaglandins, and leukotrienes, reducing nasal inflammation.
Budesonide is a corticosteroid with anti-inflammatory activity; its mechanism includes inhibition of multiple inflammatory cell types and mediators. Formoterol is a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle by increasing cyclic AMP.
1 spray per nostril twice daily (137 mcg azelastine hydrochloride and 50 mcg fluticasone propionate per spray).
Two inhalations (budesonide 160 mcg/formoterol 4.5 mcg per inhalation) twice daily (morning and evening). Maximum dose: 2 inhalations twice daily.
None Documented
None Documented
Azelastine: ~25 hours (range 22-27 h). Fluticasone propionate: ~7.8 hours intranasal; 7-8 hours IV; context: intranasal dosing achieves steady-state in 1-2 weeks.
Budesonide: 2-3 hours. Formoterol: 10-14 hours. Clinically, twice-daily dosing maintains effect due to active metabolite accumulation.
Azelastine: 75% renal (as unchanged drug and metabolites), 25% fecal. Fluticasone propionate: primarily fecal after IV (90%), renal <5%; after intranasal, significant first-pass hepatic metabolism to inactive metabolites excreted in bile and feces.
Budesonide: 60% renal metabolites, 40% fecal. Formoterol: 60% renal, 40% fecal via biliary, with 10% unchanged drug.
Category A/B
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid/Long-Acting Beta Agonist